Our founder and CEO Peter Hamley shares his perspective on AI in drug discovery in a new opinion piece in European Biotechnology Magazine (EBM).

He argues that, while AI has already improved the efficiency of molecule design, raising success rates in clinical trials requires more. In a landscape reshaped by huge investments in a few techbios, he makes the case that smaller teams can have an outsized impact when they bring together the right expertise, laser-focussed on the right biology, and equipped with new AI tools to sharpen biological hypotheses.

And that’s exactly what we’re doing at Scripta Therapeutics. We combine deep transcription factor expertise with frontier-level AI and bioinformatics; building on conventional drug discovery to identify truly disease‑modifying therapies with a higher chance of helping patients.

📌 Read the article here: https://european-biotechnology.com/opinion/where-will-ai-actually-move-the-needle-in-drug-discovery